Data from the ADRIATIC trial surprisingly suggests the survival benefit of consolidation Durvalumab was more pronounced in patients receiving carboplatin versus cisplatin. This finding reassures clinicians about using the better-tolerated carboplatin in combination with chemoradiation for limited-stage small cell lung cancer, challenging the traditional preference for cisplatin.
Modern practice is shifting away from routine Prophylactic Cranial Irradiation (PCI) for extensive-stage small cell lung cancer. This change is driven by a key Japanese study where patients, screened with baseline MRI, showed a survival trend favoring observation with serial MRIs over PCI, challenging a long-standing treatment paradigm.
Unlike traditional cytotoxic agents, the DLL3-targeting T-cell engager tarlatumab demonstrates consistent overall survival benefits in third-line SCLC regardless of the patient's chemotherapy-free interval from first-line therapy. This indicates it works via a distinct mechanism that bypasses conventional chemoresistance pathways, representing a new treatment paradigm.
The B7H3-targeted antibody-drug conjugate (ADC) ifanatumab deruxtecan shows a high intracranial response rate in SCLC, numerically even better than its systemic response rate. This suggests excellent CNS penetration, offering a promising strategy for managing brain metastases, a common and difficult challenge in SCLC.
Lurbinectedin's effectiveness in second-line SCLC is highly dependent on the chemotherapy-free interval after first-line treatment. Patients with a longer interval (>90 days) show significantly better response rates and disease control, reinforcing that "platinum sensitivity" acts as a proxy for broader cytotoxic drug sensitivity.
For very early-stage small cell lung cancer, surgical resection is an important and perhaps underutilized option. Beyond its therapeutic potential, surgery provides a definitive pathological diagnosis, which is crucial as some cases that appear to be small cell on biopsy may actually be other tumor types, like atypical carcinoid.